N-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)acetamide
• 英文别名: 2-[2-(4-Acetamidophenoxy)ethoxy]ethanol；N-[4-[2-(2-hydroxyethoxy)ethoxy]phenyl]acetamide
• 化学式: C₁₂H₁₇NO₄
• mdl: MFCD01995468
• 分子量: 239.271
• InChiKey: WJLIUDRXSMWBNY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  67.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)acetamide 在 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以69%的产率得到2-(2-(4-aminophenoxy)ethoxy)ethanol
  参考文献：
  名称：

  Clipping and stoppering anion templated synthesis of a [2]rotaxane host system

  摘要：

  一种新的 [2]rotaxane 宿主体系包含硝基异酞酰胺大环和聚醚官能化吡啶鎓轴成分，该体系是通过氯阴离子模板的剪切和堵塞合成方法制备的。移除氯阴离子模板后，1H NMR 滴定实验显示，在竞争性水性溶剂混合物中，独特的互锁主腔对氯化物和溴化物的结合具有高度选择性，而对碱性氧阴离子的结合则具有优先选择性。事实证明，与单个大环和轴组分相比，轮烷宿主系统是一种更优越的阴离子络合剂。我们还通过分子动力学模拟研究了新型轮烷的阴离子结合亲和力，所获得的结构数据总体上证实了实验溶液阴离子识别行为。

  DOI：

  10.1039/c1dt10887e
• 作为产物：
  描述：

  对乙酰氨基酚 、 二乙二醇单对甲苯磺酸酯 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 48.0h， 以72%的产率得到N-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)acetamide
  参考文献：
  名称：

  Clipping and stoppering anion templated synthesis of a [2]rotaxane host system

  摘要：

  一种新的 [2]rotaxane 宿主体系包含硝基异酞酰胺大环和聚醚官能化吡啶鎓轴成分，该体系是通过氯阴离子模板的剪切和堵塞合成方法制备的。移除氯阴离子模板后，1H NMR 滴定实验显示，在竞争性水性溶剂混合物中，独特的互锁主腔对氯化物和溴化物的结合具有高度选择性，而对碱性氧阴离子的结合则具有优先选择性。事实证明，与单个大环和轴组分相比，轮烷宿主系统是一种更优越的阴离子络合剂。我们还通过分子动力学模拟研究了新型轮烷的阴离子结合亲和力，所获得的结构数据总体上证实了实验溶液阴离子识别行为。

  DOI：

  10.1039/c1dt10887e

文献信息

• 5-Substituted pyrimidine derivatives active against internal animal
  申请人：ICI Australia Limited

  公开号：US04460588A1

  公开（公告）日：1984-07-17

  The invention concerns a process for killing internal parasites, especially trematodes or nematodes, affecting warm blooded animals such as cattle, sheep and goats by administering an effective amount of a composition containing as active ingredient a compound of the formula ##STR1## Certain of the compounds of formula I are novel and in further embodiments the invention provides novel compounds and compositions for use in the process of the invention. The process of the invention is especially applicable to the tretment of warm blooded animals infected with the trematodes Fasciola hepatica (liver fluke).

  这项发明涉及一种用于杀灭内寄生虫，特别是影响牛、羊和山羊等温血动物的颚口目或线虫的过程，通过给予含有作为活性成分的化合物的有效量的组合物。公式如下：某些公式I的化合物是新颖的，在进一步的实施中，该发明提供了新颖的化合物和组合物，用于该发明的过程。该发明的过程特别适用于治疗感染肝吸虫（Fasciola hepatica）的颚口目的温血动物。
• Parasiticidal heterocyclic ether derivatives, processes for the manufacture thereof and compositions thereof
  申请人：ICI AUSTRALIA LIMITED

  公开号：EP0015124A1

  公开（公告）日：1980-09-03

  The invention concerns parasiticidal heterocyclic ether derivatives of the formula I:- wherein W is the group -Zm-(CR1R2)n-(CHR3)p-(O-(CHR4)q-(CHR5)r-)sin which Z is oxygen or sulphur, R', R2, R3, and R4 and R5 are independently chosen from hydrogen and C1 to C6 alkyl, m is 0 or 1, n, p, q, r and s are independently 0 or an integer from 1 to 6, provided that m is 0 when n and p are both 0, s is 0 when q and r are both 0, and n +p+s(q +r) is not greaterthan 12; A, B, D, E and V are independently chosen from the group consisting of hydrogen, halogen, nitro, amino, cyano, hydroxy, mercapto, thiocyano, carboxy, formyl, C2 to C6 alkanoyl, (C1 to C6 alkoxy) carbonyl, C, to C6 alkyl optionally substituted with one or more substituents chosen from halogen, phenyl and C, to C6 alkoxy, C1 to C6 alkoxy optionally substituted with one or more substituents chosen from halogen, phenyl and C1 to C6 alkoxy; C2 to C6 alkenyl optionally substituted with one or more substituents chosen from halogen, phenyl and C, to C6 alkoxy, phenyl optionally substituted with one or more substituents chosen from halogen, C1 to C6 alkyl, C, to C6 alkoxy, nitro and cyano, phenoxy optionally substituted with one or more substituents chosen from halogen, C1 to C6 alkyl, C, to C6 alkoxy, nitro and cyano, C1 to C6 alkylthio optionally substituted with one or more substituents chosen from halogen, phenyl and C1 to C6 alkoxy, (C2 to C6 alkanoyl)amino, (C1 to C6 alkyl)amino and di(C, to C6 alkyl)amino ; F is chosen from isothiocyano and NR6R7, wherein R6 is chosen from hydrogen and C1 to C6 alkyl and R7 is chosen from hydrogen, C, to C6 alkyl optionally substituted with one or more substituents chosen from halogen, phenyl and C1 to C6 alkoxy, C2 to C6 alkenyl optionally substituted with one or more substituents chosen from halogen, phenyl and C1 to C6 alkoxy, and the group in which Y is oxygen or sulphur and R8 is chosen from C1 to C6 alkyl optionally substituted with one or more substituents chosen from halogen, phenyl and C1 to C6 alkoxy, C2 to C6 alkenyl optionally substituted with one or more substituents chosen from halogen, phenyl and C1 to C6 alkoxy, provided that Fis not isothiocyano when A, B, D, E and V are chosen from amino, hydroxy, mercapto, thiocyaho, carboxy, (C2 to C6 alkanoyl)amino and C1 to C6 alkyl)amino; and X is oxygen or sulphur; or salts thereof; processes for the manufacture thereof; and compositions thereof. The compounds of formula I are especially useful for -treating warm-blooded animals infected with the trematodes Fasciola hepatica (liver fluke).

  本发明涉及式 I 所示的寄生虫杂环醚衍生物：- W 是一个基团。 其中 W 为基团 -Zm-(CR1R2)n-(CHR3)p-(O-(CHR4)q-(CHR5)r-)sin其中 Z 是氧或硫，R'、R2、R3 和 R4 和 R5 独立地选自氢和 C1 至 C6 烷基，m 是 0 或 1，n、p、q、r 和 s 独立地为 0 或 1 至 6 的整数，条件是当 n 和 p 均为 0 时，m 为 0；当 q 和 r 均为 0 时，s 为 0；且 n +p+s(q +r) 不大于 12；A、B、D、E 和 V 独立地选自氢、卤素、硝基、氨基、氰基、羟基、巯基、硫氰基、羧基、甲酰基、 C2 至 C6 烷酰基、（C1 至 C6 烷氧基）羰基、任选被一个或多个选自卤素、苯基和 C1 至 C6 烷氧基的取代基取代的 C1 至 C6 烷基、任选被一个或多个选自卤素、苯基和 C1 至 C6 烷氧基的取代基取代的 C1 至 C6 烷氧基组成的组；C2 至 C6 烯基任选被一个或多个选自卤素、苯基和 C1 至 C6 烷氧基的取代基取代，苯基任选被一个或多个选自卤素、C1 至 C6 烷基、C1 至 C6 烷氧基、硝基和氰基的取代基取代、任选被一个或多个选自卤素、C1 至 C6 烷基、C, 至 C6 烷氧基、硝基和氰基的取代基取代的苯氧基，任选被一个或多个选自卤素、苯基和 C1 至 C6 烷氧基的取代基取代的 C1 至 C6 烷硫基，(C2 至 C6 烷酰基)氨基，(C1 至 C6 烷基)氨基和二(C, 至 C6 烷基)氨基；F 选自异硫氰基和 NR6R7，其中 R6 选自氢和 C1 至 C6 烷基，R7 选自氢、任选被一个或多个选自卤素、苯基和 C1 至 C6 烷氧基的取代基取代的 C1 至 C6 烷基、任选被一个或多个选自卤素、苯基和 C1 至 C6 烷氧基的取代基取代的 C2 至 C6 烯基，以及以下基团 其中 Y 是氧或硫，R8 选自被一个或多个选自卤素、苯基和 C1 至 C6 烷氧基的取代基任选取代的 C1 至 C6 烷基，被一个或多个选自卤素、苯基和 C1 至 C6 烷氧基的取代基任选取代的 C2 至 C6 烯基，条件是当 A、B、D、E 和 V 选自氨基、羟基、巯基、硫代巯基、羧基、（C2 至 C6 烷酰基）氨基和 C1 至 C6 烷基）氨基时，Fis 不是异硫氰酸基；X 为氧或硫；或其盐；其制造工艺；及其组合物。 式 I 的化合物尤其适用于治疗感染肝吸虫的温血动物。
• Novel cc-1065 Analogs and Their Conjugates
  申请人：Beusker Patrick Henry

  公开号：US20110207767A1

  公开（公告）日：2011-08-25

  This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.
• NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS
  申请人：Beusker Patrick Henry

  公开号：US20130224227A1

  公开（公告）日：2013-08-29

  This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.
• Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers
  申请人：SYNTARGA BV

  公开号：US20170274090A1

  公开（公告）日：2017-09-28

  This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.